Ultragenyx Pharmaceutical (RARE) Change in Account Payables (2013 - 2019)
Ultragenyx Pharmaceutical (RARE) reported Change in Account Payables of $3.9 million for Q3 2019, up 298.58% year-over-year from $980987.5 in Q3 2018, and up 211.94% on a QoQ basis from -$3.5 million in Q2 2019.
Ultragenyx Pharmaceutical (RARE) has 7 years of Change in Account Payables data on file, last reported at $3.9 million in Q3 2019.
- Quarterly Change in Account Payables rose 298.58% year-over-year to $3.9 million in Q3 2019, while the trailing twelve-month figure through Sep 2019 was $4.2 million (up 517.67% YoY) and the FY2018 annual result came in at $3.4 million, down 2.52% from the prior year.
- Change in Account Payables climbed to $3.9 million in Q3 2019 per RARE's latest filing, from -$3.5 million in the prior quarter.
- Across five years, Change in Account Payables topped out at $4.3 million in Q2 2015 and bottomed at -$5.3 million in Q3 2015.
- The 5-year median for Change in Account Payables is $187000.0 (2016), against an average of $400894.7.
- Peak annual rise in Change in Account Payables reached 4528.57% in 2015, while the deepest fall reached 825.92% in 2015.
- Tracing RARE's Change in Account Payables over 5 years: stood at -$1.4 million in 2015, then gained by 6.82% to -$1.3 million in 2016, then jumped by 68.66% to -$420000.0 in 2017, then jumped by 1044.05% to $4.0 million in 2018, then declined by 1.39% to $3.9 million in 2019.
- Per Business Quant, the three latest RARE Change in Account Payables figures stand at $3.9 million (Q3 2019), -$3.5 million (Q2 2019), and -$151000.0 (Q1 2019).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -3.26 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 35.60 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | - |
| 10 | Ultragenyx Pharmaceutical | 2.29 Bn | 1.89 Bn | 106.00 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2019 | 3.91 Mn |
| Sep 30, 2019 | 3.91 Mn |
| Jun 30, 2019 | -3.49 Mn |
| Jun 30, 2019 | -3.49 Mn |
| Mar 31, 2019 | -151,000.00 |
| Mar 31, 2019 | -151,000.00 |
| Dec 31, 2018 | 3.97 Mn |
| Dec 31, 2018 | 3.97 Mn |
| Sep 30, 2018 | -1.97 Mn |
| Sep 30, 2018 | -1.97 Mn |
| Jun 30, 2018 | 2.69 Mn |
| Jun 30, 2018 | 2.69 Mn |
| Mar 31, 2018 | -1.32 Mn |
| Mar 31, 2018 | -1.32 Mn |
| Dec 31, 2017 | -420,000.00 |
| Dec 31, 2017 | -420,000.00 |
| Sep 30, 2017 | -2.47 Mn |
| Sep 30, 2017 | -2.47 Mn |
| Jun 30, 2017 | 3.36 Mn |
| Jun 30, 2017 | 3.36 Mn |
| Mar 31, 2017 | 2.99 Mn |
| Mar 31, 2017 | 2.99 Mn |
| Dec 31, 2016 | -1.34 Mn |
| Dec 31, 2016 | -1.34 Mn |
| Sep 30, 2016 | 1.02 Mn |
| Sep 30, 2016 | 1.02 Mn |
| Jun 30, 2016 | 187,000.00 |
| Jun 30, 2016 | 187,000.00 |
| Mar 31, 2016 | 2.64 Mn |
| Mar 31, 2016 | 2.64 Mn |
| Dec 31, 2015 | -1.44 Mn |
| Dec 31, 2015 | -1.44 Mn |
| Sep 30, 2015 | -5.32 Mn |
| Sep 30, 2015 | -5.32 Mn |
| Jun 30, 2015 | 4.34 Mn |
| Jun 30, 2015 | 4.34 Mn |
| Mar 31, 2015 | 437,000.00 |
| Mar 31, 2015 | 437,000.00 |
| Dec 31, 2014 | 484,000.00 |
| Dec 31, 2014 | 484,000.00 |
| Sep 30, 2014 | 733,000.00 |
| Sep 30, 2014 | 733,000.00 |
| Jun 30, 2014 | -98,000.00 |
| Jun 30, 2014 | -98,000.00 |
| Mar 31, 2014 | 2.06 Mn |
| Mar 31, 2014 | 2.06 Mn |
| Dec 31, 2013 | -1.45 Mn |
| Dec 31, 2013 | -1.45 Mn |
| Sep 30, 2013 | 804,000.00 |
| Sep 30, 2013 | 804,000.00 |
| Jun 30, 2013 | -453,000.00 |
| Jun 30, 2013 | -453,000.00 |
| Mar 31, 2013 | 1.34 Mn |
| Mar 31, 2013 | 1.34 Mn |